JP5252682B2 - 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 - Google Patents
哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 Download PDFInfo
- Publication number
- JP5252682B2 JP5252682B2 JP2007504833A JP2007504833A JP5252682B2 JP 5252682 B2 JP5252682 B2 JP 5252682B2 JP 2007504833 A JP2007504833 A JP 2007504833A JP 2007504833 A JP2007504833 A JP 2007504833A JP 5252682 B2 JP5252682 B2 JP 5252682B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cancer
- cytokine
- biological
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004127 Cytokines Human genes 0.000 title claims description 56
- 108090000695 Cytokines Proteins 0.000 title claims description 56
- 238000000034 method Methods 0.000 title claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 32
- 201000010099 disease Diseases 0.000 title description 31
- 210000001744 T-lymphocyte Anatomy 0.000 title description 3
- 238000004458 analytical method Methods 0.000 title description 2
- 230000002265 prevention Effects 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 26
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 23
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 23
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 23
- 230000003834 intracellular effect Effects 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 108010074328 Interferon-gamma Proteins 0.000 claims description 10
- 238000005259 measurement Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 102000004388 Interleukin-4 Human genes 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 8
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 229940028885 interleukin-4 Drugs 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000008512 biological response Effects 0.000 claims 5
- 206010036790 Productive cough Diseases 0.000 claims 4
- 210000003802 sputum Anatomy 0.000 claims 4
- 208000024794 sputum Diseases 0.000 claims 4
- 238000001994 activation Methods 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000006757 chemical reactions by type Methods 0.000 claims 1
- 238000012790 confirmation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 230000004044 response Effects 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 15
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 11
- 239000007787 solid Substances 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000007985 Erythema Infectiosum Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 230000029225 intracellular protein transport Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006697 redox regulation Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
5才令の雄のゴールデンレトリバー(顔面腫瘍及び左眼球突出の症状)を使用した。MR撮像によりシストを伴った腫瘤を確認し、ダイナミックMR撮像法により悪性腫瘍と診断した。
(Thサイトカイン陽性CD4陽性細胞数/CD4陽性細胞数)×100(%)、
によって定義される。
次に良性腫瘍の例について説明する。レドックス状態が酸化を呈したので、腫瘤中の活性型TGF−β1(Transforming Growth Factor-β1:Th3反応) を測定した結果は以下の通りである。
活性型あるいは潜在型Th2反応サイトカイン/TGF−β1の産生
潜在型/活性型TGF−β1 ( ng /ml )
血漿中 正常値1.70(イヌの潜在型、活性型は検出-)
血漿中 潜在型4.94 活性型 -
腫瘤内 潜在型 +↑ 活性型18.88
このような結果、治療法を変更して治療したところ活性型TGF−β1は検出されず臨床症状(治療法変更後56日現在)は著しく改善された。
次に、パラダイムパターンから、疾病の診断や予測を自動的に可能にする例について説明する。正常犬、非正常犬(悪性腫瘍、良性腫瘍や感染症など)について、実施例1に基づいて各サイトカイン反応を測定する。Th1,Th2,Th3の各軸からなる3次元の座標空間に、各サイトカインの反応量(細胞数)をトラップする。次いで、この素データを最小二乗法によって因子軸を決定する。この因子軸に直角に交わる因子軸を追加して、この二つの2次元の座標軸に基づいて、各測定値の相関係数を算出する。
正常レベル:グレーティング≦a
良性腫瘍 :a<グレーティング≦b
悪性腫瘍 :b<グレーティング
の関係を定めることができる。したがって、ある検査対象である固体についての各Th反応を測定し、その測定値に基づいてパラダイムパターンを形成して基準線を求め、これを予め定まっているグレーティングのレベルと比較することによって、外科的な検査や遺伝子診断などの、本願発明の検査項目として説明されたもの以外の検査を行うことなしに、検査固体の疾病診断或いは将来の発症を予見することができる。なお、グレーティングのレベルの決定に必要な検査対象固体として、種別、体重別、年齢別、性別などの区別は必要ではないが、ある項目について検査対象固体を区別してもよい。
図5は、実施例1と同様にして得た、良性腫瘍の場合におけるパラダイムパターンである。表現型Th1/Th2/Th3反応、細胞内在型Th1/Th2/Th3反応のいずれにおいても、Th3の割合が少ないことが分かる。即ち、既述のグレーティングの評価とTh3の割合の評価によって、悪性腫瘍と良性腫瘍の区別をTh反応のパラダイムパターンから可能になることが分かる。なお、悪性腫瘍および良性腫瘍の場合のパラダイムパターンにおいて、Th1に対してTh2の値が増加している点において共通するものの、Th3の値については、後者のものが前者のものに比較して顕著に小さくなっていることがわかる。すなわち、Th1に比較してTh2が大きい場合に腫瘍の存在が疑われ、Th3の値が大きいことによって悪性腫瘍の存在が疑われる。さらに、良性腫瘍の場合、各Th反応のパラダイムパターンを表現型および内在型で比較すると、表現型のものではTh3では、基準線より上に相関係数の値が位置しているのに対して、内在型ものでは基準線より下に相関係数の値が位置している。悪性腫瘍の場合は、Th3の相関係数の値は表現型および内在型とも基準線より上に位置している。これによっても、悪性腫瘍および良性腫瘍の区別が可能となる。
Claims (15)
- 哺乳動物のTh1、Th2、及びTh3生体反応の各Th細胞内サイトカインを測定する工程と、各サイトカインのパラダイムパターンを求める工程と、パラダイムパターンと癌又は腫瘍とを関連付ける工程と、を備え、前記Th1、Th2、及びTh3生体反応の各Th細胞内サイトカインが順番に、インターフェロン−γ、インターロイキン−4、TGF-β1である、哺乳動物のサイトカインの分析方法。
- 前記パラダイムパターンと癌又は腫瘍とを関連付ける工程が、前記パラダイムパターンのグレーティングのレベルを予め定まっている癌又は腫瘍に関するグレーティングのレベルと比較することを含む、請求項1に記載の方法。
- 前記Th1、Th2、及びTh3の少なくとも一つのあるいは複数のTh生体反応を制御する薬剤を前記Th細胞を含む液に添加する工程を含む、請求項1または2に記載の方法。
- 体液中の前記サイトカインを測定する工程をさらに備える、請求項1〜3のいずれか一項に記載の方法。
- 前記Th細胞内サイトカインを測定する工程は、表現型Th生体反応と細胞内在型Th生体反応を測定する工程を備える、請求項1〜4のいずれか一項に記載の方法。
- 前記パラダイムパターンに、レドックス制御、Th3生体反応に加えTGF-β1の活性化の行程の評価結果、ならびにΝΚ及び/又はΝΚΤ細胞活性の測定値の少なくとも一つを組み合わせて、癌又は腫瘍を関連付ける、請求項1〜5のいずれか一項に記載の方法。
- 前記レドックス制御が、表現型あるいは細胞内在型TGF-β1に規定される前記Th3生体反応を調整する、請求項6に記載の方法。
- 哺乳動物のTh1、Th2、及びTh3生体反応の各Th細胞内サイトカインを測定する第1工程であって、前記Th1、Th2、及びTh3生体反応の各Th細胞内サイトカインが順番に、インターフェロン−γ、インターロイキン−4、TGF-β1である工程と、測定値をコンピュータに入力する第2工程と、コンピュータを用いて各Th生体反応のパラダイムパターンを求める第3工程と、前記パラダイムパターンをモニタに表示する工程と、コンピュータの演算手段が、当該パラダイムパターンと、予めメモリに記憶された、癌又は腫瘍に於ける既知のパラダイムパターンとを比較する第4工程と、を備える、哺乳動物の各Th生体反応の型及びその組み合わせならびに癌又は腫瘍の病態の分析方法。
- 前記第4工程が、前記パラダイムパターンのグレーティングのレベルを予め定まっている癌又は腫瘍に関するグレーティングのレベルと比較することを含む、請求項8に記載の方法。
- 前記コンピュータの演算手段が、前記比較の結果、測定されたパラダイムパターンの図示化から、測定対象個体の癌又は腫瘍或いは癌又は腫瘍の病態とその治療方法を特定する第5工程を備える、請求項9に記載の方法。
- 前記サイトカインを測定する工程は、表現型Th生体反応と細胞内在型Th生体反応を測定する工程を備える、請求項8〜10のいずれか一項に記載の方法。
- 前記パラダイムパターンに、レドックス制御、Th3生体反応に加えTGF-β1の活性化の行程の評価結果、ならびにΝΚ及び/又はΝΚΤ細胞活性の測定値の少なくとも一つを組み合わせて、癌又は腫瘍を関連付ける、請求項8〜11のいずれか一項に記載の方法。
- 前記レドックス制御が、表現型あるいは細胞内在型TGF-β1に規定される前記Th3反応を調整する、請求項12に記載の方法。
- Th3生体反応とTh3サイトカインである表現型TGF-β1の増加と異常な上昇の確認と、これに関連したTh3生体反応の優位性(増強)、さらにレドックス制御の偏重固定化、その結果誘導されるTh1生体反応及び細胞内在型Th1生体反応とTh2生体反応とのアンバランスならびに生体反応の低下に基づく、癌又は腫瘍のテーラーメイド療法の評価方法であって、Th1、Th2、及びTh3生体反応の各Th細胞内サイトカインの測定に基づき、かつ、前記Th1、Th2、及びTh3生体反応の各Th細胞内サイトカインが順番に、インターフェロン−γ、インターロイキン−4、TGF-β1である、評価方法。
- 前記パラダイムパターンのグレーティングのレベルを予め定まっている癌又は腫瘍に関するグレーティングのレベルと比較することを含む、請求項14に記載の評価方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007504833A JP5252682B2 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005051809 | 2005-02-25 | ||
JP2005051809 | 2005-02-25 | ||
JP2007504833A JP5252682B2 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
PCT/JP2006/303577 WO2006090874A1 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006090874A1 JPWO2006090874A1 (ja) | 2008-07-24 |
JP5252682B2 true JP5252682B2 (ja) | 2013-07-31 |
Family
ID=36927504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007504833A Active JP5252682B2 (ja) | 2005-02-25 | 2006-02-27 | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5252682B2 (ja) |
WO (1) | WO2006090874A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140023656A1 (en) * | 2010-09-24 | 2014-01-23 | BioLT CO., LTD. | Pharmaceutical composition for treatment and prevention of th3 march-related diseases |
EP3104177B1 (en) * | 2011-12-21 | 2020-11-25 | Beckman Coulter, Inc. | Method for labeling intracellular and extracellular targets of leukocytes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002513765A (ja) * | 1998-05-07 | 2002-05-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫応答の調節における無視された標的組織抗原の使用 |
JP2004503468A (ja) * | 2000-03-29 | 2004-02-05 | エラスムス ユニフェルシテイト ロッテルダム | 免疫調節物 |
-
2006
- 2006-02-27 WO PCT/JP2006/303577 patent/WO2006090874A1/ja active Application Filing
- 2006-02-27 JP JP2007504833A patent/JP5252682B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002513765A (ja) * | 1998-05-07 | 2002-05-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫応答の調節における無視された標的組織抗原の使用 |
JP2004503468A (ja) * | 2000-03-29 | 2004-02-05 | エラスムス ユニフェルシテイト ロッテルダム | 免疫調節物 |
Non-Patent Citations (11)
Title |
---|
JPN6012007285; 大塚宜一, 消化管とTGF-beta, 小児科臨床, Vol.54, No.9, 2001, p. 1693〜1700 * |
JPN6012007286; 古市賢吾, 腎疾患と炎症, 血管医学, Vol.4, No.5, 2003, p.499-506 * |
JPN6012007288; GIOMI, B., Th1, Th2 and Th3 cytokines in the pathogenesis ofbullous pemphigoid, Journal of Dermatolo * |
JPN6012007289; 堀内泉, ヘルパーT細胞と脱髄疾患, 内科, Vol.88, No.4, 2001, p.738-741 * |
JPN6012007291; 小野三佳, Th1/Th2パラダイムから検討した加齢によるアトピー性皮膚炎の差異, 日本小児アレルギー学 * |
JPN6012007292; TURCANU, V., Cell identification and isolation on the basis ofcytokine secretion: A novel tool for i * |
JPN6012007293; PEREZ-MACHADO, M. A., Reduced transforming growthfactor-beta1-producing T cells in the duodenal mucosa * |
JPN6012007294; CHRISTENSEN, H. R., Lactobacilli Differentially ModulateExpression of Cytokines and Maturation Surfa * |
JPN6012039132; 癌と化学療法 Vol.31, No.11, Page.1649-1651, 2004 * |
JPN6012039134; Int J Cancer Vol.77, No.1, Page.7-12, 1998 * |
JPN6012039135; 日本免疫学会総会・学術集会記録 Vol.22, Page.580 1K-17, 1992 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006090874A1 (ja) | 2008-07-24 |
WO2006090874A1 (ja) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leung et al. | The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype | |
Gustafson et al. | Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis | |
Morita et al. | Stratum corneum TARC level is a new indicator of lesional skin inflammation in atopic dermatitis | |
Smits et al. | Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome | |
Long et al. | 8OHdG as a marker for Huntington disease progression | |
Lanni et al. | Conformationally altered p53: a novel Alzheimer's disease marker? | |
WO2007100782A2 (en) | Biomarkers for amyotrophic lateral sclerosis and methods using the same | |
JP2017535763A (ja) | マーカー群および該マーカー群の脳損傷における使用 | |
Czarnowicki et al. | Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases | |
Ma et al. | Serum levels of ApoA1 and ApoA2 are associated with cognitive status in older men | |
JP2005502345A (ja) | 炎症性疾患を罹患した患者の薬物感受性を予測する方法 | |
TW201606304A (zh) | 測定治療反應之方法 | |
Daunt et al. | Polygenic risk scoring is an effective approach to predict those individuals most likely to decline cognitively due to Alzheimer’s disease | |
Félix Garza et al. | Characterization of disease-specific cellular abundance profiles of chronic inflammatory skin conditions from deconvolution of biopsy samples | |
Diamandis et al. | Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia | |
Costa et al. | Metabolic syndrome and the decreased levels of uric acid by leflunomide favor redox imbalance in patients with rheumatoid arthritis | |
Wimmer et al. | Microglia pre-activation and neurodegeneration precipitate neuroinflammation without exacerbating tissue injury in experimental autoimmune encephalomyelitis | |
JP5252682B2 (ja) | 哺乳動物t細胞のサイトカインの分析方法と関連する一切の疾患の評価法と予防・治療の分析 | |
Luft et al. | Heritable aspects of salt sensitivity | |
Shin et al. | B cells from periodontal disease patients express surface Toll-like receptor 4 | |
Senouci et al. | The diagnostic role of salivary biomarkers of oxidative stress and inflammatory status and their relationship in periodontitis stage III and grade C | |
JP2004531244A (ja) | アルツハイマー病の診断スクリーニング | |
Kuiper et al. | A network of serum proteins predict the need for systemic immunomodulatory therapy at diagnosis in noninfectious uveitis | |
Buhelt et al. | Biomarkers of systemic inflammation, soluble IL-2Rα and the multiple sclerosis-associated IL2RA SNP rs2104286 in healthy subjects and multiple sclerosis patients | |
JP2020525765A (ja) | Il−10、s100bおよびh−fabpマーカー群ならびに該マーカー群の外傷性脳損傷の検出における使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130401 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130415 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5252682 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |